Short, plain-language guides on GLP-1 therapy and metabolic health, written and reviewed by ZIVOLABS doctors. No clickbait. No miracle promises.
Browse the full article libraryYes — it's specifically approved for weight management in non-diabetics meeting BMI criteria, and is used safely that way worldwide.
Rarely. Mild injection-site reactions are common and harmless; true allergy (facial/throat swelling, breathing difficulty) is a medical emergency — stop and seek help immediately.
No. Compounded or grey-market 'research peptides' aren't approved in India, aren't quality-controlled, and have caused real harm. Use only licensed, branded medication.
Rare but important: pancreatitis (severe upper-belly pain to the back), gallbladder attacks, severe dehydration, and serious allergic reactions. These need prompt medical attention.
Yes — several GLP-1 medicines have been shown to reduce major cardiovascular events in high-risk patients, which is a meaningful added benefit.
You can stop without a dangerous withdrawal, but appetite — and often weight — tends to come back. A planned step-down to a maintenance dose is usually better.
No. GLP-1 medicines aren't addictive and don't cause withdrawal in that sense. Appetite does return after stopping, but that's biology resuming, not dependence.
No real tolerance develops. What changes is your body: as you lose weight your calorie needs fall, which can look like a plateau but isn't the drug weakening.
No — it tends to improve the liver, especially in fatty liver disease, where weight loss reduces liver fat and inflammation.
On the contrary, it's often kidney-protective. The main risk is indirect: severe vomiting or diarrhoea causing dehydration, which can stress the kidneys — so stay hydrated.
In humans the data don't show increased cancer overall. A rodent thyroid-tumour signal led to caution, so people with medullary thyroid cancer or MEN-2 are excluded as a precaution.
The evidence to date is reassuring — large trials run for years show a good safety profile, including cardiovascular benefit. Long-term real-world data keeps accumulating.
